Oncolytics Biotech Future Growth
Future criteria checks 2/6
Oncolytics Biotech is forecast to grow earnings and revenue by 37.5% and 72.5% per annum respectively while EPS is expected to grow by 41% per annum.
Key information
37.5%
Earnings growth rate
41.0%
EPS growth rate
| Biotechs earnings growth | 34.8% |
| Revenue growth rate | 72.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -44 | -78 | -73 | 5 |
| 12/31/2025 | 1 | -44 | -86 | -52 | 7 |
| 12/31/2024 | N/A | -34 | -38 | -33 | 7 |
| 9/30/2024 | N/A | -28 | -25 | -25 | N/A |
| 6/30/2024 | N/A | -28 | -27 | -26 | N/A |
| 3/31/2024 | N/A | -28 | -28 | -28 | N/A |
| 12/31/2023 | N/A | -28 | -28 | -28 | N/A |
| 9/30/2023 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2023 | N/A | -27 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -24 | -25 | -25 | N/A |
| 12/31/2022 | N/A | -25 | -23 | -23 | N/A |
| 9/30/2022 | N/A | -24 | -24 | -24 | N/A |
| 6/30/2022 | N/A | -24 | -24 | -23 | N/A |
| 3/31/2022 | N/A | -27 | -23 | -23 | N/A |
| 12/31/2021 | N/A | -26 | -23 | -22 | N/A |
| 9/30/2021 | N/A | -28 | -22 | -22 | N/A |
| 6/30/2021 | N/A | -30 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -29 | -24 | -24 | N/A |
| 12/31/2020 | N/A | -23 | -22 | -22 | N/A |
| 9/30/2020 | N/A | -33 | -24 | -24 | N/A |
| 6/30/2020 | N/A | -29 | -22 | -22 | N/A |
| 3/31/2020 | N/A | -28 | -20 | -20 | N/A |
| 12/31/2019 | N/A | -33 | -20 | -20 | N/A |
| 9/30/2019 | N/A | -19 | -17 | -17 | N/A |
| 6/30/2019 | N/A | -18 | -16 | -16 | N/A |
| 3/31/2019 | N/A | -17 | -11 | -11 | N/A |
| 12/31/2018 | N/A | -17 | -12 | -12 | N/A |
| 9/30/2018 | N/A | -17 | -11 | -11 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -10 | N/A |
| 3/31/2018 | N/A | -17 | N/A | -16 | N/A |
| 12/31/2017 | N/A | -16 | N/A | -15 | N/A |
| 9/30/2017 | N/A | -16 | N/A | -15 | N/A |
| 6/30/2017 | N/A | -16 | N/A | -15 | N/A |
| 3/31/2017 | N/A | -15 | N/A | -13 | N/A |
| 12/31/2016 | N/A | -15 | N/A | -12 | N/A |
| 9/30/2016 | N/A | -13 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -13 | N/A | -13 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -15 | N/A |
| 12/31/2015 | N/A | -14 | N/A | -15 | N/A |
| 9/30/2015 | N/A | -14 | N/A | -14 | N/A |
| 6/30/2015 | N/A | -16 | N/A | -16 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -16 | N/A |
| 12/31/2014 | N/A | -19 | N/A | -20 | N/A |
| 9/30/2014 | N/A | -21 | N/A | -21 | N/A |
| 6/30/2014 | N/A | -22 | N/A | -23 | N/A |
| 3/31/2014 | N/A | -22 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONC's revenue (72.5% per year) is forecast to grow faster than the Canadian market (7.1% per year).
High Growth Revenue: ONC's revenue (72.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:11 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncolytics Biotech Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| John Newman | Canaccord Genuity |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |